UK-US Pharma Deal Faced Investigation Request
Parliamentary leaders are questioning the value of a trade deal that modified NHS drug evaluation criteria.
Updated on Sept. 21, 2026 in Healthcare
Live Poll
Do you trust that government pharmaceutical trade deals prioritize the financial interests of the public?
Six parliamentary committee chairs have requested that the National Audit Office investigate the UK-US pharmaceuticals deal announced in December 2025. The inquiry seeks to determine if the agreement, which altered drug cost-effectiveness thresholds, provides value for money.
Why it matters
The deal mandates a 25% increase in funding for innovative treatments and revised evaluation methods, prompting concerns over potential long-term costs to the NHS. Committee chairs initiated the request after being unable to secure impact assessments from the government regarding the agreement.
The agreement includes a commitment to boost funding for innovative treatments by 25% and established a US tariff-free period for UK pharmaceutical products lasting from 1 January 2026 to 19 January 2029. The deal is tied to a reported extra cost to the NHS of £3bn.
The players
National Audit Office
An independent public body that audits government departments and investigates the value for money of public spending.
National Institute for Health and Care Excellence
The UK body responsible for providing national guidance and advice on the promotion of health and the prevention and treatment of ill health.
The details
The deal fundamentally changes how the National Institute for Health and Care Excellence (NICE) assesses drugs, recently enabling the approval of the breast cancer treatment Enhertu after a 2024 rejection. By increasing cost-effectiveness thresholds, the government has created a new pathway for drug adoption while committing to higher public spending. The committees are now scrutinizing whether these structural changes represent a sustainable fiscal strategy.
Timeline
NICE initially rejected the drug Enhertu in 2024.
The UK-US pharmaceuticals deal was announced in December 2025.
The US tariff-free period for UK pharmaceuticals began on 1 January 2026.
Committee chairs sent the letter to the National Audit Office on 15 September 2026.
The US tariff-free period for UK pharmaceutical products ends on 19 January 2029.
Market Landscape
The investigation request highlights the tension between international trade commitments and the National Institute for Health and Care Excellence drug approval process. It follows a pattern where government-level deals override established independent cost-effectiveness benchmarks.
Operators in the pharmaceutical sector should monitor whether the National Audit Office initiates a formal audit, as findings could influence future UK-US trade terms or NHS procurement criteria. Management teams should track how adjusted cost-effectiveness thresholds impact the competitive viability of drug pipelines.
The takeaway
The scrutiny of this deal underscores the risk when trade agreements mandate specific domestic health spending and evaluation shifts. Businesses should monitor if the National Audit Office adds this to its work programme, as a formal investigation could signal a broader policy reversal regarding NHS budget allocations.
Further reading
For more on industry regulatory shifts, see the Healthcare section.
Source note: This article includes information reported by The Pharmaceutical Journal.
Live Poll
Do you trust that government pharmaceutical trade deals prioritize the financial interests of the public?
